The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and SensitizesMYCN-Amplified NeuroblastomaIn Vivo
- 1 November 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (11) , 2115-2123
Abstract
Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and cytokinesis. Aurora A and B kinase overexpression has also been associated with various human cancers, and as such, they have been extensively studied as novel antimitotic drug targets. Here, we characterize the Aurora kinase inhibitor CCT137690, a highly selective, orally bioavailable imidazo[4,5-b]pyridine derivative that inhibits Aurora A and B kinases with low nanomolar IC50 values in both biochemical and cellular assays and exhibits antiproliferative activity against a wide range of human solid tumor cell lines. CCT137690 efficiently inhibits histone H3 and transforming acidic coiled-coil 3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumor cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy, and apoptosis. This is accompanied by p53/p21/BAX induction, thymidine kinase 1 downregulation, and PARP cleavage. Furthermore, CCT137690 treatment of MYCN-amplified neuroblastoma cell lines inhibits cell proliferation and decreases MYCN protein expression. Importantly, in a transgenic mouse model of neuroblastoma that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation, this compound significantly inhibits tumor growth. The potent preclinical activity of CCT137690 suggests that this inhibitor may benefit patients with MYCN-amplified neuroblastoma. Mol Cancer Ther; 10(11); 2115–23. ©2011 AACR.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Shared and separate functions of polo-like kinases and aurora kinases in cancerNature Reviews Cancer, 2010
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)Pediatric Blood & Cancer, 2010
- Stabilization of N-Myc Is a Critical Function of Aurora A in Human NeuroblastomaCancer Cell, 2009
- Roles of Aurora Kinases in Mitosis and TumorigenesisMolecular Cancer Research, 2007
- Childhood tumors of the nervous system as disorders of normal developmentCurrent Opinion in Pediatrics, 2006
- Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in NeuroblastomaCancer Research, 2006
- Aurora-A — A guardian of polesNature Reviews Cancer, 2005
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of NeuroblastomaJNCI: Journal of the National Cancer Institute, 2003